Pfizer will price Paxlovid at $1,390 per treatment course when selling directly to health insurers beginning in 2024. That’s about 2.6 times higher than the $529 the federal government paid for the antiviral after it launched in late 2021. Pfizer plans to subsidize copays for commercially insured patients at least through 2028. Pfizer has reduced…

Pfizer (NYSE:PFE) has reached an agreement to supply as many as six million courses of its oral COVID-19 antiviral Paxlovid (nirmatrelvir and ritonavir) to the Global Fund, which seeks to help more than 100 low-to-middle income countries fight diseases such as COVID-19, HIV, tuberculosis and malaria. Pfizer notes that the agreement with the Global Fund is…

Hyderabad, India–based Zenara Pharma has launched a generic version of Pfizer’s (NYSE:PFE) COVID-19 antiviral Paxlovid (nirmatrelvir and ritonavir). Zenara Pharma is naming the generic version of the pill “Paxzen.” The antiviral is indicated for mild to moderate symptoms of COVID-19. India’s Central Drugs Standard Control Organisation (CDSCO) cleared the way for authorization of the drug…

Pfizer’s (NYSE:PFE) CEO Dr. Albert Bourla acknowledged in a statement that he has COVID-19.  Bourla, who is 60, has received four doses of the Pfizer-BioNTech Comirnaty vaccine. He also has begun taking a course of the company’s antiviral Paxlovid.  The Pfizer CEO notes that symptoms to date have been very mild.   Pfizer’s revenue has soared during the…

FDA has revised the Emergency Use Authorization (EUA) for Pfizer’s (NYSE:PFE) Paxlovid (nirmatrelvir and ritonavir) to allow state-licensed pharmacists to prescribe the drug to some patients with a high risk of COVID-19. While the move allows pharmacists to prescribe Paxlovid, it has limits. It instructs the professionals to refer patients to a physician if there is insufficient…

Pfizer (NYSE:PFE) announced that its COVID-19 antiviral Paxlovid failed to reach statistical significance in reducing risk after patients were exposed to the SARS-CoV-2 virus. The primary endpoint of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study was to reduce the risk of confirmed and symptomatic COVID-19 in adults after…

White House officials have a plan to ramp up the availability of Pfizer’s COVID-19 antiviral Paxlovid, according to a report from Bloomberg. White House Covid-19 Response Coordinator Dr. Ashish Jha said that the administration would announce more details about the plans to make Paxlovid more widely available in the coming week. The administration plans to launch…

The Medicines Patent Pool (MPP) announced that it has signed agreements with 35 manufacturers to make an inexpensive version of Pfizer’s (NYSE: PFE) Paxlovid (nirmatrelvir/ritonavir) to be distributed in 95 low- and middle-income countries. Vaccination rates in many developing countries lag far behind that of wealthier countries. In Nigeria, for instance, 9.1% of the population…

President Biden said in his State of the Union address that the U.S. aims to ramp up the use of Pfizer‘s (NYSE:PFE) Plaxovid. The treatment has been in short supply since it won emergency use authorization late last year. Last year, when Merck & Co. (NYSE: MRK) and Pfizer were close to winning regulatory authorization for…

Pfizer (NYSE:PFE) revealed that its COVID-19 drug Paxlovid retained in vitro efficacy against the omicron SARS-CoV-2 variant. The company said that the research indicates that the drug can potentially maintain plasma concentrates “many-fold” times higher than the level needed to prevent replication of the highly transmissible variant. “These data suggest that our oral COVID-19 therapy…